Gliosarcoma - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Gliosarcoma - Pipeline Review, H2 2016

Gliosarcoma - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Gliosarcoma - Pipeline Review, H2 2016
Published Nov 09, 2016
141 pages — Published Nov 09, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gliosarcoma Pipeline Review, H2 2016, provides an overview of the Gliosarcoma (Oncology) pipeline landscape.

Gliosarcoma is a type of brain tumor that originates from glial cells. The tumor grows rapidly and symptom will vary depending on the exact location and size of the tumor. Most likely they may be headache, vomiting, cognitive problems, and drowsiness. Treatment of brain tumors depends upon the type and staging of the tumor, its size and position in the brain, as well as the age and other health problems of patient.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gliosarcoma Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Gliosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gliosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gliosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 12, 7 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.Gliosarcoma.

Gliosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Gliosarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Gliosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gliosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gliosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gliosarcoma (Oncology)

Reasons to buy

- Procure strategically important competitor information,

  
Source:
Document ID
GMDHC8633IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Gliosarcoma Overview81
Therapeutics Development92
  Pipeline Products for Gliosarcoma Overview91
  Pipeline Products for Gliosarcoma Comparative Analysis101
Gliosarcoma Therapeutics under Development by Companies112
Gliosarcoma Therapeutics under Investigation by Universities/Institutes131
Gliosarcoma Pipeline Products Glance142
  Clinical Stage Products141
  Early Stage Products151
Gliosarcoma Products under Development by Companies161
Gliosarcoma Products under Investigation by Universities/Institutes171
Gliosarcoma Companies Involved in Therapeutics Development1814
  Amgen Inc.181
  Axelar AB191
  Bristol-Myers Squibb Company201
  Burzynski Research Institute, Inc.211
  Celgene Corporation221
  Cortice Biosciences, Inc.231
  ERC Belgium SA241
  Merck &Co., Inc.251
  Millennium Pharmaceuticals Inc261
  NewLink Genetics Corporation271
  Novartis AG281
  Nuo Therapeutics, Inc.291
  Progenics Pharmaceuticals, Inc.301
  Triphase Accelerator Corporation311
Gliosarcoma Therapeutics Assessment3212
  Assessment by Monotherapy Products321
  Assessment by Combination Products331
  Assessment by Target343
  Assessment by Mechanism of Action373
  Assessment by Route of Administration402
  Assessment by Molecule Type422
Drug Profiles4494
  ALD-451 Drug Profile441
  alisertib Drug Profile455
  Antineoplaston Therapy Drug Profile504
  AXL-1717 Drug Profile542
  CC-122 Drug Profile562
  dasatinib Drug Profile582
  DNX-2401 Drug Profile603
  ERC-1671 Drug Profile631
  flucytosine + TBio-01 Drug Profile641
  indoximod Drug Profile655
  irinotecan hydrochloride + TBio-02 Drug Profile701
  lonafarnib Drug Profile712
  M-032 Drug Profile731
  marizomib Drug Profile744
  p28 Drug Profile782
  pazopanib hydrochloride Drug Profile807
  pembrolizumab Drug Profile8737
  PSMA ADC Drug Profile1244
  rilotumumab Drug Profile1282
  RRX-001 Drug Profile1302
  TPI-287 Drug Profile1324
  urelumab Drug Profile1362
Gliosarcoma Dormant Projects1381
Gliosarcoma Product Development Milestones1391
  Featured News &Press Releases1391
    Nov 26, 2013: Burzynski Clinic Presents the Successful Treatment of a Child with Recurrent Diffuse Intrinsic Pontine Gliosarcoma at the Congress1391
Appendix1402
  Methodology1401
  Coverage1401
  Secondary Research1401
  Primary Research1401
  Expert Panel Validation1401
  Contact Us1401
  Disclaimer1411

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Gliosarcoma - Pipeline Review, H2 2016" Nov 09, 2016. Alacra Store. May 04, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Gliosarcoma-Pipeline-Review-H2-2016-2088-16762>
  
APA:
Global Markets Direct - Market Research. (2016). Gliosarcoma - Pipeline Review, H2 2016 Nov 09, 2016. New York, NY: Alacra Store. Retrieved May 04, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Gliosarcoma-Pipeline-Review-H2-2016-2088-16762>
  
US$ 2,000.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.